$8 Billion Risperdal Judgment Reduced to $6.8 Million

$8 Billion Risperdal Judgment Reduced to $6.8 Million

$8 Billion Risperdal Judgment Reduced to $6.8 Million

The judge presiding over a case which saw Johnson & Johnson hit with an $8bn jury verdict has reduced the amount the company has to pay in damages to $6.8m.

Last October,  J&J was ordered to pay $8bn in damages to a US man who claims he was not warned that taking the company’s antipsychotic Risperdal could lead to breast growth.

A jury in Philadelphia agreed with the allegation that J&J’s Janssen unit had downplayed the risk that use of Risperdal (risperidone) in male children can cause enlarged breasts, a condition known as gynaecomastia.


About TriMark

TriMark Legal Funding provides Risperdal pre settlement funding to injured plaintiffs nationwide.

This post originally appeared here: https://www.pmlive.com/pharma_news/updated_j_and_js_$8bn_risperdal_judgment_reduced_to_$6.8m_1312458

Click here to see the full original article.

Still have questions?

Call (877) 932-2628 and speak with one of our legal funding experts.

* Word-Use Disclaimer

Legal funding is not a loan. It is the non-recourse purchase of an equitable lien in plaintiffs’ legal claims. Words such as ‘loans,’ ‘lending,’ ‘borrow,’ etc., are used for marketing purposes only.
More info

TriMark Legal Funding LLC
1056 Green Acres Rd #102
Eugene, OR 97408